TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01417481

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
Study: NCT01298011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Abraxane
Description: 3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
Study: NCT01273012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic - Infloran
Description: Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic - Infloran
Description: Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
Study: NCT00408408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg IV
Study: NCT02343809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actual Diacutaneous Fibrolysis
Description: Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Diacutaneous Fibrolysis
Description: Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.

Intervention type: OTHER
Group type: OTHER
Intervention: Protocolized Physiotherapy
Description: Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocolized Physiotherapy
Description: Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Protocolized Physiotherapy
Description: Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
Study: NCT03736876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: About Us
Description: Each program session includes an initial soap opera-like story to build interest and illustrate key concepts, 2-3 group-based activities with reflection, individual app-based work on tablets to allow for personalization of the content, and a group-based debrief to reflect on the day and reinforce key messages. The group-based content is delivered by trained facilitators from the participating school-based health centers. The app-based content is housed on a secure website and accessed through tablets with unique log-ins for each participant. Activities are completed individually during the session (e.g., completing a poll; watching and responding to a brief video). Several lessons include homework activities that encourage communication between students and a caring adult.
Study: NCT01359501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chinese medical treatment-LCH1
Description: Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
Study: NCT00408408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 15 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 orally
Study: NCT03508609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS16
Description: GCSF-mobilized autologous CD34 cells
Study: NCT02922179

Intervention type: DRUG
Intervention: Long- and intermediate- acting insulins
Description: alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea

Intervention type: DRUG
Intervention: Long- and intermediate- acting insulins
Description: alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
Study: NCT01679886

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Rubidium PET
Description: Rubidium PET
Study: NCT00345618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idrabiotaparinux sodium
Description: 0.5 mL pre-filled syringe for 3.0 mg~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)~Oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for idrabiotaparinux sodium)
Description: 0.5 mL pre-filled syringe~Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avidin
Description: 100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avidin
Description: 100 mg in 10 mg/mL solution~Intravenous infusion for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for warfarin)
Description: Warfarin matching capsules~Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Prefilled syringes as locally registered~Subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Prefilled syringes as locally registered~Subcutaneous injection
Study: NCT00250276

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: GSK Biologicals' vaccine against human papillomaviruses 16 and 18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: GSK Biologicals' vaccine against human papillomaviruses 16 and 18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: GSK Biologicals' vaccine against human papillomaviruses 16 and 18.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix™
Description: GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
Study: NCT00667849

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exogen 4000+
Description: Low-intensity pulsed ultrasound (LIPUS)
Study: NCT02271191

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicardipine
Description: nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicardipine
Description: nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
Study: NCT00667849

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: sham device identical to active device with the exception of administration of ultrasound
Study: NCT00995423

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CoroflexTM Please
Description: highly flexible CoroflexTM Please-Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting stent
Description: Paclitaxel-eluting stent
Study: NCT02366156

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo capsules consumed prior to breakfast each day for 4 weeks
Study: NCT00408408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 825 mg/m2 orally
Study: NCT02366156

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Grape Blend
Description: Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Grape Blend
Description: Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
Study: NCT05155774

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin block
Description: Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin block
Description: Twin Block orthodontic appliance for treating patients with Angle class II molar relationship and a large horizontal overjet, often in combination with an incomplete lip closure
Study: NCT03458156

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SLE group
Description: The patients will be assigned to systemic lupus erythematosus (SLE) group, receiving umbilical cord mesenchymal stem cell transplantation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LN group
Description: The patients will be assigned to lupus nephritis (LN) group, receiving umbilical cord mesenchymal stem cell transplantation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the control group
Description: The patients will be assigned to the control group.
Study: NCT03356249

Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Generation Sequencing
Description: In 500 patients with suspected or proven sepsis or septic shock (according to the Sepsis-3 definitions), patients´ characteristics and routine blood parameters will be determined at sepsis onset as well as 72 hours afterwards. At the same time points, 2 sets of blood cultures and one blood tube for Next-Generation Sequencing (NGS)-diagnostics will be collected. An evaluation of outcome will be performed at 28 days after sepsis onset.
Study: NCT04990960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: During each session (45 minutes)the patient was assessed and trained in self-treatment exercises assigned to treat their cords. This later method was chosen to ensure regular participation in their exercises and early correction of any inaccuracies in the implementation of the exercises regarding AWS treatment . Or the Physiotherapist worked actively on cords with soft or vigorous stretching.
Study: NCT03042052

Intervention type: DRUG
Intervention: detrusor infection of Botulinum toxin
Description: detrusor injection
Study: NCT04059120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group whit specific stretching
Description: The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced with specific exercises of stretching and with it the factors that determine the syndrome of overtraining

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group whit out specific stretching
Description: The intervention involves a reality of physical, physical, different exercise, similar to the realist of high-performance athletes. However, this is the physical load, which is reduced less than specific exercises of stretching and with it the factors that determine the syndrome of overtraining
Study: NCT02020317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: decision support in potassium-inc. drug-drug-interactions
Description: display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
Study: NCT03372174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maintaining mechanical ventilation during surgery
Description: dead space ventilation using tidal volume of 2.5 mL/kg/pbw (predicted body weight) with 5-7 cm H2O Positive end-expiratory pressure
Study: NCT05819333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program + Respiratory Strength Training
Description: Strength, Flexibility, Cardiovascular exercise + respiratory strength training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program + Respiratory Relaxation Training
Description: Strength, Flexibility, Cardiovascular exercise + respiratory relaxation training
Study: NCT00587756

Intervention type: PROCEDURE
Intervention: One-stage ultrasound guided hepatectomy
Description: Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
Study: NCT03372174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absence of mechanical ventilation during surgery
Description: absence of mechanical ventilation (and no Positive end-expiratory pressure) by disconnecting the tracheal tube from the ventilator
Study: NCT02211430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Counseling (CBC)
Description: Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice (BC) Control
Description: For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4).
Study: NCT01730586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
Study: NCT02714283

Intervention type: DRUG
Intervention: inhaled corticosteroid therapy
Description: We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies

Intervention type: DRUG
Intervention: macrolide therapy
Description: We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
Study: NCT00061633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin or antistaphylococcal penicillin
Description: Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
Study: NCT01979458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSE
Study: NCT02725541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: HER2-targeted antibody drug conjugate of trastuzumab and DM1
Study: NCT02400541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy
Description: Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.~Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: relaxation therapy
Description: Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
Study: NCT02387554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0904

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP0608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1405

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HGP1405
Study: NCT04487652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival recession coverage
Description: The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.
Study: NCT01107509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: 10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
Study: NCT04487652

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gingival recession coverage
Description: The Modified Coronally Advanced Tunnel technique in conjunction with a palatal subepithelial connective tissue graft will be performed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: with CoQ10 spray application
Description: After surgical recession coverage a CoQ10 spray will be applied during the early phase of wound healing.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: with placebo spray application
Description: After surgical recession coverage a placebo spray will be applied during the early phase of wound healing.
Study: NCT00988572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Description: The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
Study: NCT02248636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholinesterase inhibitor
Description: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham discontinuation
Description: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
Study: NCT03295617

Intervention type: PROCEDURE
Intervention: Thoracoscopy
Description: Thoracoscopy surgery
Study: NCT02547558

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial blood gases
Description: Measured through radial arterial catheter

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Output
Description: Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vital signs
Description: As measured in clinical practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exhaled breath
Description: Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spirometry
Description: In a daily calibrated spirometer.
Study: NCT00006214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide

Intervention type: OTHER
Group type: OTHER
Intervention: placebo
Study: NCT02758392

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 Intravenous
Description: Participants will receive JNJ-61178104 Intravenously on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61178104 Intravenous
Description: Participants will receive JNJ-61178104 Intravenously on Day 1.
Study: NCT02547558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol Breezhaler@ 300 mcg (1 inhalation)
Study: NCT02491606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine 200mg and 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine 200mg and 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine
Description: Tafenoquine 200mg and 400 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03296943

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Essential oil
Description: To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Perfume
Description: To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cue-induced inhalants craving
Description: Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Cue-induced inhalants craving
Description: Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
Study: NCT04718493

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-expandable metal stent
Description: Endoscopic stenting of intestinal stricture related to Crohn´s disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon dilatation
Description: Endoscopic balloon dilatation of intestinal stricture related to Crohn´s disease